表紙：胃がん治療薬市場規模、シェア、成長分析、タイプ別、治療タイプ別、薬剤タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

市場調査レポート

商品コード

1764770

胃がん治療薬市場規模、シェア、成長分析、タイプ別、治療タイプ別、薬剤タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

Gastric Cancer Drugs Market Size, Share, and Growth Analysis, By Type (Adenocarcinoma, Lymphoma), By Treatment Type (Chemotherapy, Targeted Therapy), By Drug Type, By Route of Administration, By End-Users, By Region - Industry Forecast 2025-2032

出版日: 2025年07月02日
発行: SkyQuest
ページ情報: 英文 195 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 782,598円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 915,492円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,048,386円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=147.66円

全表示
概要
目次

概要

サンプル依頼リストに入れる

胃がん治療薬の世界市場規模は2023年に54億米ドルと評価され、2024年の60億2,000万米ドルから2032年には143億8,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは11.5％で成長する見通しです。

世界の胃がん治療薬市場は、罹患率の上昇と医薬品開発の著しい進歩に牽引され、ダイナミックな成長を遂げようとしています。肥満、喫煙、ヘリコバクターピロリ感染などの危険因子の有病率の増加が、効果的な治療法に対する需要を高めています。標的療法や免疫療法などの革新的な治療法は治療方法に革命をもたらし、患者の転帰を改善しています。医療費の増加、旺盛な研究開発投資、支持的な規制環境に後押しされ、製薬会社、バイオ製薬会社、学術機関の戦略的提携が次世代治療の導入を促進しています。しかし、市場開拓は、高い開発コスト、厳しい規制、低所得地域でのアクセス制限などの課題に直面しています。とはいえ、多様な医薬品パイプラインは、マルチターゲット治療や個別化治療の可能性と相まって、前途有望であることを示しています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024年）

主要企業プロファイル

Imugene Limited（Australia）
Otsuka Pharmaceuticals Co., Ltd（Japan）
F. Hoffmann-La Roche Ltd（Switzerland）
Merck KGaA（Germany）
Bristol-Myers Squibb Company（U.S.）
Novartis AG（Switzerland）
Lilly（U.S.）
Sanofi（France）
Amgen Inc.（U.S.）
Bayer AG（Germany）
Gilead Sciences, Inc.（U.S.）
AstraZeneca（U.K.）
Ipsen Pharma（France）
Takeda Pharmaceutical Company Limited（Japan）
Biosplice Therapeutics, Inc.（U.S.）
Arbutus Biopharma（Canada）
ASLAN Pharmaceuticals（Singapore）

結論と提言

Product Code: SQMIG35I2393

Global Gastric Cancer Drugs Market size was valued at USD 5.4 billion in 2023 and is poised to grow from USD 6.02 billion in 2024 to USD 14.38 billion by 2032, growing at a CAGR of 11.5% during the forecast period (2025-2032).

The global gastric cancer drugs market is poised for dynamic growth, driven by rising incidence rates and significant advancements in drug development. Increased prevalence of risk factors like obesity, smoking, and Helicobacter pylori infections is escalating the demand for effective therapies. Innovations such as targeted therapies and immunotherapies are revolutionizing treatment modalities and improving patient outcomes. Boosted by higher healthcare spending, robust R&D investments, and supportive regulatory environments, strategic partnerships among drug companies, biopharmaceutical firms, and academic institutions are facilitating the introduction of next-generation treatments. However, market growth faces challenges, including high development costs, stringent regulations, and limited access in low-income regions. Nonetheless, a diverse drug pipeline, coupled with potential multi-targeted and personalized therapies, indicates a promising future ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastric Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastric Cancer Drugs Market Segments Analysis

Global Gastric Cancer Drugs Market is segmented by Type, Treatment Type, Drug Type, Route of Administration, End-Users and region. Based on Type, the market is segmented into Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Others. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation Therapy, Medication and Others. Based on Drug Type, the market is segmented into Doxorubicin Hydrochloride, Sunitinib, Mitomycin, Imatinib, Fluorouracil, Trastuzumab and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market is experiencing significant growth driven by the rapid development and approval of targeted therapies and immunotherapies. Advanced treatment options, including HER2 inhibitors and PD-1/PD-L1 checkpoint inhibitors, offer enhanced efficacy and improved safety compared to traditional chemotherapy. By effectively targeting specific genetic mutations and immune checkpoints, these innovations have unlocked new therapeutic possibilities, leading to better outcomes and increased survival rates for many gastric cancer patients. As pivotal clinical trials validate the effectiveness of these novel treatments, regulatory bodies and healthcare professionals are swiftly integrating them into practice, further propelling market expansion.

Restraints in the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market faces substantial challenges primarily due to the prohibitive costs associated with new targeted therapies and immunotherapies. These innovative treatments often come with premium price tags, a consequence of significant research and development expenses, intricate manufacturing processes, and the need for companion diagnostics. As a result, access to these advanced therapies is largely determined by financial capability, making it difficult for patients in low- and middle-income countries to obtain them. Even in high-income nations, reimbursement obstacles and budget constraints further hinder widespread adoption, restricting patient access and slowing overall market growth.

Market Trends of the Global Gastric Cancer Drugs Market

The global gastric cancer drugs market is experiencing a significant transformation, driven by rapid advancements in artificial intelligence (AI) and data analytics. AI technologies are enhancing drug development processes, allowing for more personalized treatment options tailored to the genetic profiles of patients. This trend not only optimizes therapeutic effectiveness but also improves patient outcomes, ultimately driving increased adoption of innovative drug formulations. Additionally, the integration of AI in clinical decision-making is enabling healthcare professionals to make more informed choices, resulting in a more strategic approach to managing gastric cancer. As a result, the market is poised for substantial growth, with ongoing investments in research and development further propelling innovation.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis
Case Studies

Global Gastric Cancer Drugs Market Size by Type & CAGR (2025-2032)

Market Overview
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others

Global Gastric Cancer Drugs Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Surgery
Radiation Therapy
Medication
Others

Global Gastric Cancer Drugs Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Doxorubicin Hydrochloride
Sunitinib
Mitomycin
Imatinib
Fluorouracil
Trastuzumab
Others

Global Gastric Cancer Drugs Market Size by Route of Administration & CAGR (2025-2032)

Market Overview
Oral
Injectable

Global Gastric Cancer Drugs Market Size by End-Users & CAGR (2025-2032)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Gastric Cancer Drugs Market Size & CAGR (2025-2032)

North America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- US
- Canada
Europe (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Imugene Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceuticals Co., Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biosplice Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arbutus Biopharma (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ASLAN Pharmaceuticals (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

胃がん治療薬市場規模、シェア、成長分析、タイプ別、治療タイプ別、薬剤タイプ別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

Gastric Cancer Drugs Market Size, Share, and Growth Analysis, By Type (Adenocarcinoma, Lymphoma), By Treatment Type (Chemotherapy, Targeted Therapy), By Drug Type, By Route of Administration, By End-Users, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

胃がん治療薬市場規模：タイプ別& CAGR（2025年～2032年）

胃がん治療薬市場規模：治療タイプ別& CAGR（2025年～2032年）

胃がん治療薬市場規模：薬剤タイプ別& CAGR（2025年～2032年）

胃がん治療薬市場規模：投与経路別& CAGR（2025年～2032年）

胃がん治療薬市場規模：エンドユーザー別& CAGR（2025年～2032年）

胃がん治療薬市場規模：地域別& CAGR（2025年～2032年）